About: Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial
Creator	Baran, Andrea Hulbert, Barbara Vargas, Roberto Falsey, Ann Walsh, Edward Formica, Maria Branche, Angela Peterson, Derick
source	Medline; PMC
abstract	Background. Viral lower respiratory tract illness (LRTI) frequently causes adult hospitalization and is linked to antibiotic overuse. European studies suggest that the serum procalcitonin (PCT) level may be used to guide antibiotic therapy. We conducted a trial assessing the feasibility of using PCT algorithms with viral testing to guide antibiotic use in a US hospital. Methods. Three hundred patients hospitalized with nonpneumonic LRTI during October 2013–April 2014 were randomly assigned at a ratio of 1:1 to receive standard care or PCT-guided care and viral PCR testing. The primary outcome was antibiotic exposure, and safety was assessed at 1 and 3 months. Results. Among the 151 patients in the intervention group, viruses were identified in 42% (63), and 83% (126) had PCT values of <0.25 µg/mL. There were no significant differences in antibiotic use or adverse events between intervention patients and those in the nonintervention group. Subgroup analyses revealed fewer subjects with positive results of viral testing and low PCT values who were discharged receiving antibiotics (20% vs 45%; P = .002) and shorter antibiotic durations among algorithm-adherent intervention patients versus nonintervention patients (2.0 vs 4.0 days; P = .004). Compared with historical controls (from 2008–2011), antibiotic duration in nonintervention patients decreased by 2 days (6.0 vs 4.0 days; P < .001), suggesting a study effect. Conclusions. Although antibiotic use was similar in the 2 arms, subgroup analyses of intervention patients suggest that physicians responded to viral and biomarker data. These data can inform the design of future US studies. Clinical Trials Registration. NCT01907659.
has issue date	2015-04-24(xsd:dateTime)
bibo:doi	10.1093/infdis/jiv252
bibo:pmid	25910632
has license	bronze-oa
sha1sum (hex)	c8260c55e3605f2474cd9adb5fb722675f64bf6e
schema:url	https://doi.org/10.1093/infdis/jiv252
resource representing a document's title	Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial
has PubMed Central identifier	PMC4633755
has PubMed identifier	25910632
schema:publication	Journal of Infectious Diseases
resource representing a document's body	covid:c8260c55e3605f2474cd9adb5fb722675f64bf6e#body_text
is schema:about of	named entity 'illness' named entity 'conducted' named entity 'Randomized Controlled Trial' named entity 'OVERUSE' named entity 'ALGORITHMS' named entity 'CAUSES' named entity 'PROCALCITONIN' named entity 'HOSPITAL' named entity 'PCT' named entity 'RESPIRATORY INFECTIONS' named entity 'ADULTS' named entity 'TO GUIDE' named entity 'SUGGEST' named entity 'EUROPEAN' covid:arg/c8260c55e3605f2474cd9adb5fb722675f64bf6e named entity 'STUDIES' named entity 'VIRAL' named entity 'ADULT' named entity 'ANTIBIOTIC THERAPY' named entity 'ANTIBIOTIC' named entity 'TRIAL' named entity 'LEVEL' named entity 'USED' named entity 'LOWER RESPIRATORY TRACT' named entity 'SERUM' named entity 'RANDOMIZED CONTROLLED TRIAL' named entity 'TESTING' named entity 'FEASIBILITY' named entity 'VIRAL' named entity 'ANTIBIOTIC USE' named entity 'PROCALCITONIN MEASUREMENT' named entity 'SERUM' named entity 'ASSESSING' named entity 'FREQUENTLY' named entity 'TESTING' named entity 'ILLNESS' named entity 'TO GUIDE' named entity 'HOSPITALIZED' named entity 'USING' named entity 'MAY BE' named entity 'HOSPITALIZATION' named entity 'BACKGROUND' named entity 'therapy' named entity 'antibiotic' named entity 'adult' named entity 'hospitalization' named entity 'Viral' named entity 'Respiratory Infections' named entity 'Viral Testing' named entity 'European studies' named entity 'standard treatment' named entity 'Rochester, New York' named entity 'viral testing' named entity 'legionella' named entity 'guided care' named entity 'diagnostic tests' named entity 'bacterial infections' named entity 'respiratory infections' named entity 'antibiotic' named entity 'guided care' named entity 'long-term' named entity 'biomarkers' named entity 'chest radiograph' named entity 'antibiotic' named entity 'antibiotic' named entity 'guided care' named entity 'respiratory illnesses' named entity 'antibiotics' named entity 'antibiotic' named entity 'hospital stays' named entity 'antibiotic' named entity '8 days' named entity 'human metapneumovirus' named entity 'coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software